Pelthos Therapeutics Inc.PTHS财报
NYSE
Pelthos Therapeutics Inc.是一家临床阶段生物制药企业，专注于研发针对罕见代谢及内分泌疾病的靶向创新疗法，核心管线覆盖多款存在高度未满足临床需求的适应症，主要业务布局于北美及欧洲市场。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| Ezra Friedberg | 9.50% | 545.7K | — | 2024-02-26 |
| Motif Pharmaceuticals Ltd. | 8.40% | 483.4K | — | 2024-03-01 |
| Boswell Prayer Ltd | 8.20% | 471.6K | — | 2024-03-04 |
| Aperture Healthcare Ventures Ltd. | 7.70% | 444.1K | — | 2024-03-01 |
| Benuvia Operations, LLC | 6.70% | 384.2K | — | 2024-03-01 |
| AME Equities LLC | 6.40% | 369.2K | — | 2024-03-01 |
| Maier Joshua Tarlow | 5.50% | 318.8K | — | 2024-03-01 |
| Tikkun Capital LLC | 4.99% | 301.0K | — | 2024-11-13 |
内部人交易
Net 90d: −$57.1K · buys $0 / sells $57.1K时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-02 | Richard Malamut | Director | Sell (open market) | 310 | $20.51 | $6.4K |
| 2026-04-02 | Richard Malamut | Director | Sell (open market) | 280 | $21.36 | $6.0K |
| 2026-04-02 | Peter Greenleaf | Director | Sell (open market) | 420 | $20.52 | $8.6K |
| 2026-04-02 | Peter Greenleaf | Director | Sell (open market) | 377 | $21.36 | $8.1K |
| 2026-04-02 | Friedberg Ezra M | Director | Sell (open market) | 293 | $20.51 | $6.0K |
| 2026-04-02 | Friedberg Ezra M | Director | Sell (open market) | 265 | $21.36 | $5.7K |
| 2026-04-02 | Matthew Pauls | Director | Sell (open market) | 415 | $20.52 | $8.5K |
| 2026-04-02 | Matthew Pauls | Director | Sell (open market) | 371 | $21.36 | $7.9K |
1–8 of 8